Clinical Trial Update: An Exploratory Clinical Study of Anti-CD19 CAR NK Cell (KN5501) in the Treatment of Relapsed/Refractory Immune Nephropathy [EARLY_Phase 1]

View source ↗

Summary

Exploratory Phase 1 trial evaluating KN5501, an anti-CD19 CAR NK cell, for relapsed/refractory immune nephropathy. The study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nephropathy

Drugs mentioned

• KN5501 (anti-CD19 CAR NK cell)

Snippet

Sponsor: Changhai Hospital | Conditions: Nephropathy | EARLY_Phase 1 | Status: RECRUITING